Related Experiment Videos

Rituximab for post-transplant recurrences of FSGS

Umut Selda Bayrakci1, Esra Baskin, Hale Sakalli

  • 1Department of Pediatric Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey.

Pediatric Transplantation
|September 30, 2008
PubMed

Insights

Rituximab effectively treated severe post-transplant proteinuria recurrence in a young FSGS patient. This B-cell depleting therapy achieved remission, demonstrating its potential for managing Focal Segmental Glomerulosclerosis (FSGS) recurrence after kidney transplantation.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Focal Segmental Glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome in children and adults.
  • Recurrence of FSGS post-kidney transplantation is a significant clinical challenge, often leading to graft dysfunction.
  • Standard immunosuppressive therapies can be insufficient in preventing or treating FSGS recurrence.

Observation:

  • A 14-year-old boy with primary FSGS experienced severe proteinuria immediately after a second living-related kidney transplant.
  • Despite conventional immunosuppression (steroids, cyclosporine A, daclizumab, mycophenolate mofetil), proteinuria and serum creatinine levels worsened.
  • Rituximab was administered on post-transplant day four.

Findings:

  • Four weekly doses of rituximab (375 mg/m(2)/dose) led to rapid depletion of circulating CD19-positive B cells.
  • Remission of proteinuria was achieved six weeks after initiating rituximab treatment.
  • Excellent graft function was maintained six months post-transplantation, with minimal proteinuria.

Implications:

  • Rituximab represents a promising therapeutic option for managing post-transplant FSGS recurrence.
  • Targeting B cells with rituximab may offer a more effective strategy than conventional immunosuppression in select cases.
  • This case highlights the potential of novel immunotherapies in improving outcomes for kidney transplant recipients with recurrent FSGS.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...